Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
antineoplastic agent |
| gptkbp:ATCCode |
L01XX41
|
| gptkbp:CASNumber |
35943-35-2
|
| gptkbp:chemicalFormula |
C12H15N5O3
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:cancer
|
| gptkbp:discoveredBy |
1970s
|
| https://www.w3.org/2000/01/rdf-schema#label |
triciribine
|
| gptkbp:is_a_nucleoside_analog |
true
|
| gptkbp:is_investigational_drug |
true
|
| gptkbp:mechanismOfAction |
Akt inhibitor
|
| gptkbp:molecularWeight |
277.28 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL178
6235 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
fatigue myelosuppression |
| gptkbp:synonym |
API-2
PTX-200 6-amino-4-methyl-8-(β-D-ribofuranosylamino)pyrrolo[2,3-d]pyrimidine |
| gptkbp:target |
gptkb:Akt1
gptkb:Akt2 gptkb:Akt3 |
| gptkbp:UNII |
6T3D8G1G1E
|
| gptkbp:bfsParent |
gptkb:AKT_(protein_kinase_B)
|
| gptkbp:bfsLayer |
6
|